Market Place
Sourcing Support
Aquestive Therapeutics Reports Q3 2024 Results and Business Update
04 Nov 2024 //
GLOBENEWSWIRE
Aquestive Presents Analysis of Anaphylm™ Study at ACAAI 2024
25 Oct 2024 //
GLOBENEWSWIRE
Aquestive Announces Positive Results From OAS Challenge Study
24 Oct 2024 //
GLOBENEWSWIRE
Aquestive Therapeutics Reports Q3 2024 Results & Call On Nov 5
21 Oct 2024 //
GLOBENEWSWIRE
Aquestive Therapeutics Spotlights Epinephrine Delivery Pipeline
27 Sep 2024 //
GLOBENEWSWIRE
Aquestive Therapeutics To Hold Virtual Investor Day
09 Sep 2024 //
GLOBENEWSWIRE
Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences
22 Aug 2024 //
GLOBENEWSWIRE
Aquestive Comments On FDA Approval Of Non-Injection Epinephrine For Anaphylaxis
14 Aug 2024 //
GLOBENEWSWIRE
Aquestive Therapeutics Reports Q2 2024 Results And Business Update
06 Aug 2024 //
GLOBENEWSWIRE
Aquestive Reports Positive Data For Anaphylm Self-Administration Study
25 Jul 2024 //
GLOBENEWSWIRE
Aquestive To Report Q2 2024 Results On August 6, Call On August 7
23 Jul 2024 //
GLOBENEWSWIRE
Aquestive to Participate in Leerink Partners Therapeutics Forum I&I & Metabolism
27 Jun 2024 //
GLOBENEWSWIRE
Aquestive eports Positive Data from Anaphylm™ Sublingual Film Study
25 Jun 2024 //
GLOBENEWSWIRE
Aquestive To Join Russell 3000® And Russell 2000® Indexes
18 Jun 2024 //
GLOBENEWSWIRE
Aquestive Appoints Executives, Builds Commercial Capabilities
03 Jun 2024 //
GLOBENEWSWIRE
Aquestive: Epinephrine Sublingual Film PK/PD Data At Allergy Conference
28 May 2024 //
GLOBENEWSWIRE
Aquestive At JMP Life Sciences Conference 2024
09 May 2024 //
GLOBENEWSWIRE
Aquestive Therapeutics Q1 2024 Results and Business Update
06 May 2024 //
GLOBENEWSWIRE
Aquestive Reports Q1 2024 on May 7, Call on May 8
25 Apr 2024 //
GLOBENEWSWIRE
Aquestive: Libervant Crossover Data At AAN 2024
12 Apr 2024 //
GLOBENEWSWIRE
Aquestive Strengthens Board of Directors with Experienced Biotech Executive
01 Apr 2024 //
GLOBENEWSWIRE
Aquestive Therapeutics Announces Closing of Underwritten PO of Common Stock
25 Mar 2024 //
GLOBENEWSWIRE
Aquestive Therapeutics Announces Proposed Public Offering of Common Stock
19 Mar 2024 //
GLOBENEWSWIRE
Aquestive Announces Pricing of $75 M Underwritten PO of Common Stock
19 Mar 2024 //
GLOBENEWSWIRE
Aquestive Therapeutics Announces Pivotal Study for Anaphylm
14 Mar 2024 //
GLOBENEWSWIRE
Aquestive Therapeutics Reports Full Year 2023 Financial Results
05 Mar 2024 //
GLOBENEWSWIRE
Aquestive Therapeutics to Report Fourth Quarter 2023 Financial Results
21 Feb 2024 //
GLOBENEWSWIRE
Aquestive Therapeutics to Present Anaphylm Sublingual Film Data
15 Feb 2024 //
GLOBENEWSWIRE
Aquestive to Participate in Oppenheimer 34th Annual Healthcare Conference
30 Jan 2024 //
GLOBENEWSWIRE
Aquestive Doses First Patient in Phase 3 Study Evaluating Pharmacokinetics
05 Dec 2023 //
GLOBENEWSWIRE
Aquestive to Present Data from Pharmacokinetic & Pharmacodynamic Studies
10 Nov 2023 //
GLOBENEWSWIRE
Aquestive Therapeutics Reports Third Quarter 2023 Financial Results
06 Nov 2023 //
GLOBENEWSWIRE
Aquestive Therapeutics Completes $45 Million Debt Refinancing
02 Nov 2023 //
GLOBENEWSWIRE
Aquestive Therapeutics to Report Third Quarter 2023 Financial Results
31 Oct 2023 //
GLOBENEWSWIRE
Aquestive Therapeutics Provides Business Update
09 Oct 2023 //
GLOBENEWSWIRE
Aquestive Reaffirms Timeline and Pathway for Anaphylm Sublingual Film
20 Sep 2023 //
GLOBENEWSWIRE
Aquestive Therapeutics Receives FDA Acceptance of NDA for Libervant
11 Sep 2023 //
GLOBENEWSWIRE
Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences
23 Aug 2023 //
GLOBENEWSWIRE
Aquestive Therapeutics Reports Second Quarter 2023 Financial Results
07 Aug 2023 //
GLOBENEWSWIRE
Aquestive to Participate in 2023 Wedbush PacGrow Healthcare Conference
02 Aug 2023 //
GLOBENEWSWIRE
Aquestive Therapeutics Announces Positive Pharmacokinetic Data for Anaphylm
27 Jul 2023 //
GLOBENEWSWIRE
Aquestive to Present Positive Data from Studies of Anaphylm
25 Jul 2023 //
GLOBENEWSWIRE
Aquestive Therapeutics to Report Second Quarter 2023 Financial Results
25 Jul 2023 //
GLOBENEWSWIRE
Aquestive to Present +VE Data from Pharmacokinetic & Pharmacodynamic of Anaphylm
06 Jul 2023 //
GLOBENEWSWIRE
Aquestive Provides Business Update and Announces CMO Appointment
29 Jun 2023 //
GLOBENEWSWIRE
Aquestive Reports Results from Studies Evaluating Performance of Anaphylm
31 May 2023 //
GLOBENEWSWIRE
Aquestive Therapeutics Reports 1Q 2023 FYR and Provides Business Update
02 May 2023 //
GLOBENEWSWIRE
Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences
26 Apr 2023 //
GLOBENEWSWIRE
Aquestive Therapeutics Receives Conditional FDA Acceptance of Proprietary Name
20 Apr 2023 //
GLOBENEWSWIRE
Aquestive to Report 1Q 2023 FYR and Recent Business Highlights on May 2
18 Apr 2023 //
GLOBENEWSWIRE
Aquestive Expands Libervant License/Supply Agreement with Pharmanovia
29 Mar 2023 //
CONTRACT PHARMA
Aquestive Therapeutics Reports Fourth Quarter & Full Year 2022 Financial Results
07 Mar 2023 //
GLOBENEWSWIRE
Aquestive Therapeutics to Participate in Oppenheimer 33rd Annual Healthcare
01 Mar 2023 //
GLOBENEWSWIRE
Aquestive Therapeutics to Report Fourth Quarter 2022 Financial Results
22 Feb 2023 //
GLOBENEWSWIRE
Aquestive to Present Data from Pharmacokinetic & Pharmacodynamic for AQST-109
21 Feb 2023 //
GLOBENEWSWIRE
Aquestive Therapeutics Provides Business Update and Outlines Key 2023 Objectives
06 Jan 2023 //
GLOBENEWSWIRE
Aquestive Announces Completion of FDA End-of-Phase 2 Meeting For AQST-109
22 Dec 2022 //
GLOBENEWSWIRE
Aquestive Announces Publication of Food Effect Study of Diazepam Nasal Spray
29 Nov 2022 //
GLOBENEWSWIRE
Aquestive to Present Positive Data from Pharmacokinetic Studies for AQST-109
09 Nov 2022 //
GLOBENEWSWIRE
Aquestive Therapeutics Reports 3Q 2022 FYR and Provides Business Update
01 Nov 2022 //
GLOBENEWSWIRE
